Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
AIDS and HIV
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - AIDS and HIV
    Use of Lymphosum Tube to Double-Check Low CD4 Counts Is Unnecessary: Presented at ASCP - (DGDispatch)
    Neurocognitive Issues Plague HIV-Infected Patients Taking Antiretroviral Therapy: Presented at IDSA - (DGDispatch)
    Antiretroviral-Experienced Patients Maintain HIV Suppression Through 144 Weeks: Presented at IDSA - (DGDispatch)
    No Gender Differences Seen With Atazanavir Treatment for HIV Infection: Presented at IDSA - (DGDispatch)
    TopAbstracts in AIDS and HIV 10/26/2009 - (DGNews)

    News archive

     Recent webcasts/CME - AIDS and HIV
    • Improving Outcomes in HIV
    • Which Developments in HIV Are Likely to Change Practice? The Year in Review
    • Management of an HIV-Infected Patient After Initial Antiretroviral Regimen Failure
      The Use of Chemokine Receptor Antagonists in Antiretroviral Treatment Failure
      Issues in the Care of HIV and Hepatitis C Virus-coinfected Patients: Antiretroviral Pharmacokinetics, Drug Interactions, and Liver Transplantation

      Webcasts/CME archive

       Recent cases - AIDS and HIV
        Rapid and Persistent Selection of the K103N Mutation as a Majority Quasispecies in a HIV1-Patient Exposed to Efavirenz for Three Weeks: A Case Report and Review of the Literature
        Newly Formed Cystic Lesions for the Development of Pneumomediastinum in Pneumocystis Jirovecii Pneumonia
        Bordetella Bronchiseptica Pneumonia in a Man with Acquired Immunodeficiency Syndrome: A Case Report
        HIV Care for the Primary Care Physician
        Invasive Pulmonary Aspergillosis in HIV Patient with High CD4 Count

        Cases archive
          




        my personal edition > aids and hiv > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Antiretrovirals Appear Safe During Pregnancy: Presented at ACOG

        By Maggie Schwarz

        WASHINGTON, D.C. -- May 11, 2006 -- The safety of 28 antiretrovirals in HIV-positive pregnant women has been assessed in nearly 6000 pregnancies and only 1 agent was identified as being associated with a risk for birth defects, according to research presented here at the 54th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists (ACOG).

        Brenda Ross, MD, assistant professor of maternal-fetal medicine, Johns Hopkins Medical Center, Baltimore, Maryland, presented the research on a population of 5829 pregnancies registered in the multinational, voluntary, collaborative Antiretroviral Pregnancy Registry, which monitors pregnancy exposures for signals of a possible increase in the incidence of birth defects.

        Most women in the registry are taking 3 medications but they can be on just 1 to be enrolled. The median age of women whose pregnancies are registered is 28 years (range 13-48 years). Ninety percent of reports originated in the United States. Also included in the registry are the United Kingdom, France, Germany, Australia, Brazil, and South Africa, among others.

        Of 5829 evaluable pregnancies to date, 5560 resulted in live births. Of these, 2.6% involved at least 1 birth defect. The rate of birth defects reported in the general population is 3.1%, according to the Centers for Disease Control and Prevention.

        Among first-trimester antiretroviral exposures, 2.9% of 2117 of pregnancies involved a birth defect.

        The only agent to present a problem was efavirenz (Sustiva' Stocrin). Teratogenicity risk for this agent was noted and a warning included in the labeling several years ago.

        Dr. Ross concluded, "Antiretrovirals are generally safe. It's important to register patients so we can continue to determine teratogenic potential. All patients are enrolled anonymously."


        [Presentation title: The Antiretroviral Pregnancy Registry: 15 Years of Progress and 15 Years of Data. Abstract p. 41S]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send